chartexchange
ESTUTC-5 New York
Sign up
FeedbackDocs

XTLB
XTL Biopharmaceuticals Ltd.
stockNASDAQADR

At CloseNov 2, 2026 3:51:21 PM EST
1.87USD+16.149%(+0.26)12,984
1.3800Bid2.1500Ask0.7700Spread
Loading…
Loading…
Market Cap
4.23M
Sector
Healthcare
Industry
Biotechnology
CEO
Josh Levine
HQ
Ramat Gan, New York, Israel
Previous Close
$1.61
Beta
0.77
52-Week High
$5.64 2026-01-13
52-Week Low
$1.60 2026-10-30
SMA 50
$2.26
SMA 200
$2.72
Avg. Vol 10D
5,075
Avg. Vol 30D
7,735
Avg. Vol 90D
51,294
Relative Vol
1.53
Shares Out
2.46M
Float
9.23M
Free Float %
375.57%
Short Interest
4,178
Short Interest %
0.05%
Days to Cover
1.00
On/Off Exchange
64%/36%
Short Vol %
20.00%
Short Vol % (off-exch)
17.71%
Borrow Fee
89.6200%
Borrow Avail.
65,000
FTDs
13
FTDs 30d avg
13
FTDs 30d high
13
Last Split
Mar 25, 2026 · 1-for-4 (reverse)
Related
VRTXAZNGSKBMYJNJLLYPFEMRKTEVAANTHXLV
XTLB Profile

xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company's lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

XTLB Performance
PeriodPriceDateChangeBeta
1W1.822026-10-26-5.50%6.030
1M2.162026-10-02-20.37%0.377
3M2.862026-08-03-39.88%0.592
6M3.652026-05-01-52.88%1.165
1Y4.202025-11-03-59.05%0.771
2Y9.402024-11-01-81.70%—
5Y15.562021-11-02-88.95%0.469
XTLB Stock Summary

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) stock price today is $1.72, and today's volume is 11,798. XTLB is up 6.832% today. The 30 day average volume is 7,735. XTLB market cap is $4.23M with 2.46M shares outstanding.